A prospective surveillance of cardiovascular events in antiplatelet-treated arteriosclerosis obliterans patients in Japan. - SEASO

Mitsubishi Tanabe Pharma Corporation0 sites11,375 target enrollmentMarch 26, 2010

ConditionsArteriosclerosis obliterans Peripheral arterial disease

Overview

Phase: 未知
Intervention: Not specified
Conditions: Arteriosclerosis obliterans Peripheral arterial disease
Sponsor: Mitsubishi Tanabe Pharma Corporation
Enrollment: 11375
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

<Journal Articles> -Int Heart J. 51(5):337-42,2010. -Circ J. 80(3):712-21,2016. -Scientific Reports 7(1):6095,2017. -Angiology Nov26,2018. -Circ J. 83(9):1029-36,2019. <Scientific Conference> -The Annual Meeting of Japanese College of Angiology 53rd (2012) 54th (2013) 55th (2014) -The Annual Scientific Meeting of the Japanse Curculation Society 77th (2013) 78th (2014) 79th (2015) -European Society of Cardiology (2015)

Registry

who.int

Start Date

March 26, 2010

End Date

September 1, 2013

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Mitsubishi Tanabe Pharma Corporation

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•The following subjects were excluded: (1\)Those with contraindications to the use of targeted medication (sarpogrelate or antiplatelet agents). (2\)Those considered inappropriate for the study by patient's physicians.